Deferoxamina
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Deferoxamina: Evaluation Pending — Evidence Pack Incomplete
One-Sentence Summary
Deferoxamina (deferoxamine) is a well-established iron-chelating agent used clinically for iron overload conditions. However, the submitted Evidence Pack contains no TxGNN-predicted indications and no approved authorizations in the Italian market were identified, making a standard repurposing evaluation impossible at this stage — a Hold decision is required until data gaps are resolved.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no authorizations found in AIFA registry |
| Predicted New Indication | Not available — no TxGNN predictions returned |
| TxGNN Prediction Score | Not available |
| Evidence Level | N/A |
| Italy Market Status | Not marketed (0 authorizations) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why This Report Cannot Be Completed
The Evidence Pack for Deferoxamina is missing two critical inputs required to generate a repurposing evaluation:
No predicted indications were returned. The predicted_indications field is empty, meaning the TxGNN model either did not process this drug or did not return a ranked output. Without a predicted target indication, none of the core sections — mechanism linkage, clinical trial evidence, or literature review — can be populated.
No regulatory authorizations were found. The AIFA query returned zero licenses, and the drug's original approved indication is therefore not recorded in the Evidence Pack. While deferoxamine is a known chelating agent used for iron and aluminum overload in clinical practice globally, this background knowledge cannot substitute for verified regulatory source data in a formal evaluation report.
Mechanism of action data is absent. The original_moa field is flagged as a data gap (severity: High). Without MOA data, the rationale connecting the original indication to any new indication cannot be constructed.
Italy Market Information
No authorizations were found in the AIFA registry for DEFEROXAMINA at the time of this query (2026-03-29).
Note: Deferoxamine-containing products may be registered under alternative spellings (e.g., "desferrioxamine", "deferoxamine") or brand names (e.g., Desferal). A secondary query using alternate identifiers is recommended before concluding the drug is absent from the Italian market.
Safety Considerations
Please refer to the package insert for safety information. No key warnings, contraindications, or drug interaction data were retrieved for this submission.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack does not contain the minimum required inputs — a TxGNN prediction score and a target indication — to produce a repurposing evaluation. Proceeding without these would result in a report with no substantive content.
To proceed, the following is needed:
- TxGNN output: Re-run the prediction pipeline for DEFEROXAMINA and confirm that a ranked list of predicted indications is returned. If the drug node is absent from the knowledge graph, a mapping step is required first.
- AIFA registry lookup: Re-query using alternate drug name spellings and brand names (e.g., "desferrioxamine", "Desferal") to establish whether the drug is already marketed in Italy.
- DrugBank MOA data: The query log records a successful DrugBank hit (
result_count: 1), but MOA was not extracted. This data should be parsed and populated before the next pipeline run. - TFDA package insert: The query log also records a successful TFDA package insert retrieval (
result_count: 1). Extract warnings, contraindications, and indication text from this document to populate the safety fields.Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.